

41. **Finelli PF.** Primary CNS lymphoma in myasthenic on long-term azathioprine. *J Neurooncol* 2005; 74:91–92.
42. **Sanders DB, Hart IK, Mantegazza R,, et al.** An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. *Neurology* 2008; 71:400–406.
43. **Muscle Study Group.** A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. *Neurology* 2008; 71:394–399.
44. **Meriggioli MN, Ciafaloni E, Al-Hayk KA, et al.** Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. *Neurology* 2003; 61:1438–1440.
45. **Hehir MK, Burns TM, Alpers J, Conaway MR, Sawa M, Sanders DB.** Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. *Muscle Nerve* 2010; 41:593–598.
46. **Merlob P, Stahl B, Klinger G.** Tetrad of the possible mycophenolate mofetil embryopathy: a review. *Reprod Toxicol* 2009; 28:105–108.
47. **Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G.** Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. *N Engl J Med* 1987; 316:719–724.
48. **Heckmann JM, Rawoot A, Bateman K, Renison R, Badri M.** A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. *BMC Neurol* 2011; 11:97.
49. **Pasnoor M, He J, Herbelin L, Dimachkie M, Barohn RJ; Muscle Study Group.** Phase II trial of methotrexate in myasthenia gravis. *Ann N Y Acad Sci* 2012; 1275:23–28.
50. **Díaz-Manera J, Martínez-Hernández E, Querol L, et al.** Long-lasting treatment effect of rituximab in MuSK myasthenia. *Neurology* 2012; 78:189–193.
51. **Gronseth GS, Barohn RJ.** Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 2000; 55:7–15.
52. **Kumar V, Kaminski HJ.** Treatment of myasthenia gravis. *Curr Neurol Neurosci Rep* 2011; 11:89–96.
53. **Pompeo E, Tacconi F, Massa R, Mineo D, Nahmias S, Mineo TC.** Long-term outcome of thoracoscopic extended thymectomy for nonthymomatous myasthenia gravis. *Eur J Cardiothorac Surg* 2009; 36:164–169.

ADDRESS: Yuebing Li, MD, PhD, Department of Neurology, Neuromuscular Center, Neurological Institute, S90, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: Liy@ccf.org

CORRECTION

Paget disease of bone

(JULY 2013)

In the article “Paget disease of bone: Diagnosis and drug therapy” in the July 2013 issue, an error occurred on page 458, under the subheading “Intravenous bisphosphonates.” The text read, “Pamidronate was approved in 1994. Although it does not contain nitrogen, it is quite effective in many patients with Paget disease.” Pamidronate in fact does contain nitrogen.